|WIZP -- Israel Stock|| |
ILS 213.00 10.20 5.03%
The current investor indifference towards the small price fluctuations of Wize Pharma may raise some interest from investors as it closed today at a share price of 202.8
in trading volume. The company directors and management did not add any value to Wize Pharma investors in February
. However, most investors can still diversify their portfolios with Wize Pharma to hedge your portfolio against high-volatility market scenarios. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 0.0. The very small Stock volatility is a good signal to investors with longer term investment horizons. This diagnostics interface makes it easy to digest most current publicly released information about Wize Pharma as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis Wize Pharma price relationship with some important fundamental indicators such as market cap and management efficiency. See also Your Current Watchlist
Wize Pharma Note
The company recorded loss per share of 0.11. Wize Pharma had not issued any dividends in recent years. The entity had a split on 2015-01-18. Wize Pharma Ltd. develops, manufactures, and markets electrooptical systems for night vision in Israel, Switzerland, India, and internationally. For more information please call Or Eisenberg at 972 3 232 4501.
Wize Pharma Alerts
|Wize Pharma is not yet fully synchronised with the market data|
|Wize Pharma generates negative expected return over the last 30 days|
|Wize Pharma has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations|
|The company has accumulated 707K in total debt with debt to equity ratio (D/E) of 217.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Wize Pharma has Current Ratio of 0.23 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. |
|The entity reported revenue of . Net Loss for the year was (1.91M). |
|WIZE PHARMA has accumulated about 275K in cash with (1.1M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. |
The company currently falls under 'Micro-Cap' category with current market capitalization of 35.89M.
Wize Pharma has return on total asset (ROA) of (80.74) %
which means that it has lost $80.74 on every $100 spent on asset. This is way below average.
Wize Pharma Technical and Predictive Indicators